Ticker Details
Gilead Sciences, Inc. Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
IPO Date:	January 3, 1994
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$171.97B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.76 | 1.13%
Avg Daily Range (30 D):	$1.45 | 1.03%
Avg Daily Range (90 D):	$1.72 | 1.27%

Institutional Daily Volume
Avg Daily Volume:	7.87M
Avg Daily Volume (30 D):	3.69M
Avg Daily Volume (90 D):	4.68M

Trade Size
Avg Trade Size (Sh.):	147
Avg Trade Size (Sh.) (30 D):	54
Avg Trade Size (Sh.) (90 D):	59

Institutional Trades
Total Institutional Trades:	123,686
Avg Institutional Trade:	$5.5M
Avg Institutional Trade (30 D):	$21.89M
Avg Institutional Trade (90 D):	$20.53M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	21

Market Closing Trades
Avg Closing Trade:	$58.61M
Avg Closing Trade (30 D):	$213.15M
Avg Closing Trade (90 D):	$198.26M
Avg Closing Volume:	857.96K

News

Apr 16, 2026 @ 5:00 PM Non-Small Cell Lung Cancer Clinical Trial Race Int... Source: Delveinsight

Apr 8, 2026 @ 10:00 AM Nurix Therapeutics Reports First Quarter 2026 Fina... Source: Na

Apr 7, 2026 @ 4:06 PM Gilead Acquisition Spree Continues With $3 Billion... Source: Vandana Singh

Apr 6, 2026 @ 5:20 PM Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks T... Source: Jaachi Mbachu, Aci

Apr 2, 2026 @ 8:16 AM A Healthy Return: Drug Spin-off Nets Keymed Up To ... Source: Bamboo Works

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$6.84	$1.76	$6.84
Diluted EPS	$6.78	$1.74	$6.78
Revenue	$29.44B	$7.93B	$29.44B
Gross Profit	$23.21B	$6.3B	$23.21B
Net Income / Loss	$8.51B	$2.18B	$8.51B
Operating Income / Loss	$10.02B	$1.98B	$10.02B
Cost of Revenue	$6.23B	$1.62B	$6.23B
Net Cash Flow	$-2427M	$234M	$-2427M
PE Ratio	20.30

Splits
Jan 28, 2013	2:1
Jun 25, 2007	2:1
Sep 07, 2004	2:1
Mar 08, 2002	2:1
Feb 22, 2001	2:1